In the fall of 2019, Vertex launched Trikafta, the latest of its breakthrough therapies for people with cystic fibrosis. Capable of treating up to 90% of those who suffer from the progressive, life-threatening disease, the drug has already been used to treat thousands of patients in the U.S. and recently won approval in the EU. The company’s sales—$4.2 billion in 2019—have averaged 35% annual growth over the past three years. One setback: The biotech’s stock fell 23% in October after it scrapped a new drug in Phase II clinical trials.
Courtesy of Vertex
As of 5/23/2022
Market Value ($M)
Market value as of March 31, 2022.
Future 50As of 12/3/20
|Year||Revenues ($M)||Profits ($M)|